Compare Logitech International SA (LOGI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs State Street SPDR S&P Biotech ETF — how do they compare? Logitech International SA trades at $98.41 (market cap $14.46B), while State Street SPDR S&P Biotech ETF trades at $153.64 (market cap $10.11B). The key difference: Logitech International SA is the larger of the two by market cap, and Logitech International SA pays a 1.63% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LOGI | XBI | |
|---|---|---|
Market Cap | $14.46B | $10.11B |
Volume | 349,547 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $126.69 | $169.55 |
52-Week Low | $85.84 | $104.99 |
Typical Hold Time | 92 Days | 38 Days |
Enterprise Value | $12.79B | — |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $98.49, down 3.61% on the day, with a neutral technical outlook and mixed analyst sentiment. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong profitability is evident with a net income margin of 16.28% and ROE of 35.29%. Recent news highlights product launches and partnerships, including new headsets and a collaboration with SEGA.
The outlook is balanced, with potential upside to the consensus price target of $107.00, supported by solid fundamentals and innovation. Risks include competitive pressures and macroeconomic sensitivity. Analyst consensus is divided, with 26.32% buy ratings, reflecting cautious optimism amid near-term volatility.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
